Cannon Gillian

SEC Form 4 insider trading activity

Cannon Gillian has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jun 8, 2026.

On the most recent filing, Cannon Gillian is listed as Director at Xenon Pharmaceuticals Inc. Inside the rolling window, Cannon Gillian reported no open-market purchases and 1 open-market sale totaling $63K in XENE.

Companies traded

Other insiders at XENE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$63K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
XENE
Cannon Gillian
Sale$63KJun 8SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Cannon Gillian made?

Cannon Gillian has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.

Which companies does Cannon Gillian trade?

Cannon Gillian has filed SEC Form 4 disclosures for 1 company, including XENE.

When was Cannon Gillian's most recent SEC Form 4 filing?

Cannon Gillian's most recent SEC Form 4 filing on Tracefour is dated Jun 8, 2026.

What is Cannon Gillian's total buy and sell value in the current window?

Inside the rolling retention window, Cannon Gillian bought $0 and sold $63K based on SEC Form 4 filings.

What was Cannon Gillian's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 1,190 XENE shares on 2026-06-05, worth $63K, per SEC Form 4 filings.